natgillin/translations-raw huggingface dataset:
At 12 months, there was a mean reduction in liver organ volume of 12.1% and a mean reduction in spleen volume of 19.0%. 
Po 12 mesecih je bilo povprečno zmanjšanje volumna jeter 12,1 % in povprečno zmanjšanje volumna vranice 19,0 %.
The most common serious adverse reaction reported with miglustat treatment in clinical studies was peripheral neuropathy (see section 4.4). 
Najpogostejši resni neželeni učinek, o katerem so poročali pri zdravljenju z miglustatom v kliničnih študijah, je bila periferna nevropatija (glejte poglavje section 4.4).
Do not drive or use any tools or machines if you feel dizzy. 
Če ste omotični, ne vozite in ne upravljajte nobenega orodja ali strojev.
Although no direct comparisons with Enzyme Replacement Therapy (ERT) have been performed in treatment-naive patients with type 1 Gaucher disease, there is no evidence of miglustat having an efficacy or safety advantage over ERT. ERT is the standard of care for patients who require treatment for type 1 Gaucher disease (see section 5.1). 
Čeprav neposredne primerjave z zdravljenjem z encimskim nadomestnim zdravljenjem (ERTEnzyme Replacement Therapy) pri bolnikih z Gaucherevo boleznijo tipa 1, ki predhodno niso bili zdravljeni, niso bile opravljene, ni dokazov, da bi bil miglustat učinkovitejši ali varnejši kot ERT. ERT je standardna oskrba za bolnike, ki potrebujejo zdravljenje Gaucherjeve bolezni tipa 1 (glejte poglavje 5.1).
- the active substance is miglustat. 
- zUčinkovina je miglustat.
Gaucher disease is an inherited metabolic disorder caused by a failure to degrade glucosylceramide resulting in lysosomal storage of this material and widespread pathology. 
Gaucherjeva bolezen je dedna presnovna motnja, ki jo povzroča neuspešna razgradnja glukozilceramida, kar povzroči shranjevanje te snovi v lizosomih in razširjeno patologijo.
The main effects common to all species were weight loss and diarrhoea, and, at higher doses, damage to the gastrointestinal mucosa (erosions and ulceration). 
Glavni učinki, skupni vsem vrstam, so bili hujšanje in driska ter pri višjih odmerkih poškodbe sluznice prebavil (erozije in ulceracije).
Other possible side effects are muscular spasms or weakness, fatigue, chills and malaise, depression, difficulty sleeping, forgetfulness and reduced libido. 
Drugi možni neželeni učinki so mišični krči ali slabost, utrujenost, mrzlica in splošno slabo počutje, depresija, težave s spanjem, pozabljivost in zmanjšan libido.
Yargesa is indicated for the treatment of progressive neurological manifestations in adult patients and paediatric patients with Niemann-Pick type C disease (see sections 4.4, and 5.1). 
Zdravilo Yargesa je indicirano za zdravljenje progresivne nevrološke manifestacije pri odraslih bolnikih in pediatričnih bolnikih z Niemann-Pickovo boleznijo vrste C (glejte poglavji 4.4, in 5.1).
In type 1 Gaucher disease, a substance called glucosylceramide is not removed from your body. 
Pri Gaucherjevi bolezni tipa 1 se snov, imenovana glukozilceramid, ne odstranjuje iz telesa.
Niemann-Pick type C disease 
Niemann-Pickova bolezen tipa C
• For type 1 Gaucher disease: For adults, the usual dose is one capsule (100 mg) three times a day (morning, afternoon and evening). 
• Za 1 Gaucherjevo bolezen tipa 1: Za odrasle je običajni odmerek ena kapsula (100 mg) trikrat dnevno (zjutraj, popoldne, zvečer).
In clinical practice, miglustat-induced gastrointestinal events have been observed to respond to individualised diet modification (for example reduction of sucrose, lactose and other carbohydrate intake), to taking miglustat between meals, and/or to anti-diarrhoeal medicinal products such as loperamide. 
V klinični praksi so opažali prebavne dogodke, ki jih je izzval miglustat in ki so ustrezali individualni spremembi prehrane (na primer zmanjšanju vnosa saharoze, laktoze in drugih ogljikovih hidratov), jemanju miglustata med obroki ali jemanju zdravil proti driski, na primer loperamida, ali obojega.
Pharmacokinetic parameters of miglustat were assessed in healthy subjects, in a small number of patients with type 1 Gaucher disease, Fabry disease, HIV-infected patients, and in adults, adolescents and children with Niemann-Pick type C disease or type 3 Gaucher disease. 
Farmakokinetične parametre miglustata so ovrednotili pri zdravih osebah, pri majhnem številu bolnikov z Gaucherjevo boleznijo tipa 1, pri bolnikih s Fabryjevo boleznijo, pri bolnikih, okuženih z virusom HIV in pri odraslih, mladoletnikih in otrocih z Niemann-Pickovo boleznijo tipa C ali Gaucherjevo boleznijo tipa 3.
Pack size: 84 x 1 capsules. 
Velikost pakiranja: 84 x 1 kapsula.
The reason for these tests is that some patients have had tingling or numbness in the hands and feet, or a decrease in body weight, while taking Yargesa. 
Razlog za te preiskave je, da so nekateri bolniki med jemanjem zdravila Yargesa izkusili omrtvičenost ali mravljinčenje v rokah in stopalih ali zmanjšanje telesne mase.
There are no pharmacokinetic data available in patients with liver impairment, in children or adolescents with type 1 Gaucher disease or in the elderly (> 70 years). 
Na voljo ni nobenih farmakokinetičnih podatkov za bolnike z okvarjenim delovanjem jeter, otroke ali mladostnike z Gaucherjevo boleznijo tipa 1 ali starostnike (> 70 let).
Peripheral neuropathy seems to be more common in patients with type 1 Gaucher disease compared to the general population. 
Kaže, da je periferna nevropatija pogostejša pri bolnikih z Gaucherjevo boleznijo tipa 1 kot pri splošni populaciji.
Do not take Yargesa - if you are allergic to miglustat or any of the other ingredients of this medicine (listed in section 6) 
Kaj morate vedeti, preden boste vzeli zdravilo Yargesa Ne jemljite zdravilaYargesa: - če ste alergični na miglustat ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
In 11 clinical trials in different indications 247 patients were treated with miglustat at dosages of 50-200 mg t.i.d. 
V 11 kliničnih preskušanjih z različnimi indikacijami so 247 bolnikov zdravili z zdravilom Yargesa z odmerki 50-200 mg trikrat dnevno.
Monitoring of platelet counts is recommended in these patients. 
Zato se pri teh bolnikih priporoča spremljanje števila trobocitov.
If your diarrhoea does not respond to these measures, or if you have any other abdominal complaint, consult your doctor. 
Če driska po teh ukrepih ne bo izzvenela ali če imate še druge prebavne težave, se o tem posvetujte z zdravnikom.
In addition, inhibitory action on a non-lysosomal glycosylceramidase has been demonstrated experimentally in vitro. 
Poleg tega je bilo zaviralno delovanje na nelizosomalni glikozilceramidazi dokazana eksperimentalno in vitro.
Capsule shell gelatin purified water titanium dioxide (E171) 
titanov dioksid (E171)
The most common adverse reactions reported in clinical studies with miglustat were diarrhoea, flatulence, abdominal pain, weight loss and tremor (see section 4.4). 
Najpogostejši neželeni učinki, o katerih so poročali v kliničnih študijah z miglustatom, so bili driska, flatulenca, bolečina v trebuhu, izguba telesne mase in tremor (glejte poglavje 4.4).
A No Observed Effect Level (NOEL) was not established and the effect was not dose dependent. 
Ravni brez opaženega učinka (NOEL - ˝No Observed Effect Level˝) niso ugotovili,
• Yargesa is also used to treat progressive neurological symptoms in Niemann-Pick type C disease in adults and in children. 
• Zdravilo Yargesa se uporablja tudi za zdravljenje progresivnih nevroloških simptomov pri Niemann-Pickovi bolezni tipa C pri odraslih in otrocih.
Nerve conduction studies abnormal 
Preiskave Pogosto nenormalne študije prevodnosti živcev
If you do get any of these effects, please seek medical advice from your doctor as soon as possible. 
Če opazite katerega koli od teh učinkov, čim prej obvestite svojega zdravnika.
If you do lose some weight when you start treatment with Yargesa don't worry. 
Če po začetku zdravljenja z zdravilom Yargesa izgubite nekaj telesne mase, to ni razlog za zaskrbljenost.
Due to limited experience, Yargesa should be used with caution in patients with renal or hepatic impairment. 
Zaradi malo izkušenj moramo zdravilo Yargesa pri bolnikih z okvarjenim delovanjem ledvic ali jeter uporabljati previdno.
Yargesa is only used when a patient is considered unsuitable for treatment with enzyme replacement therapy. 
Yargesa se jemlje le, kadar bolnik za encimsko nadomestno zdravljenje ni primeren.
The mechanism is most likely inhibition of intestinal disaccharidases such as sucrase-isomaltase in the gastrointestinal tract leading to reduced absorption of dietary disaccharides. 
Mehanizem je najverjetneje inhibicija disaharidaz v črevesju, kot je sukraza-izomaltaza v prebavilih, kar povzroči zmanjšano absorpcijo disaharidov iz hrane.
The benefit to the patient of treatment with Yargesa should be evaluated on a regular basis (see section 4.4). 
Koristi zdravljenja z zdravilom Yargesa je treba pri bolnikih redno preverjati (glejte poglavje 4.4).
The efficacy of Yargesa in children and adolescents aged 0-17 years with type 1 Gaucher disease has not been established. 
Pediatrična populacija Učinkovitost zdravila Yargesa pri otrocih in mladostnikih, starih od 0 do 17 let, z Gaucherjevo boleznijo tipa 1, še ni bila dokazana.
Peripheral neuropathy, ataxia, amnesia, paraesthesia, hypoaesthesia, headache, dizziness 
Pogosto periferna nevropatija, ataksija, amnezija, parestezije, hipoestezija, glavobol, omotičnost
Miglustat has been administered at doses of up to 3000 mg/day for up to six months in HIV positive patients during clinical trials. 
Miglustat so v kliničnih preskušanjih uporabljali v odmerkih do 3000 mg/dan do šest mesecev pri bolnikih z okužbo z virusom HIV.
• For Niemann-Pick type C disease: For adults and adolescents (over 12 years old), the usual dose is two capsules (200 mg) three times a day (morning, afternoon and evening). 
• Za Niemann-Pickovo bolezen tipa C: Za odrasle in mladostnike (stare več kot 12 let) je običajni odmerek dve kapsuli (200 mg) trikrat dnevno (zjutraj, popoldan in zvečer).
There was no drug-related increase in tumour incidence in any other organ. 
Drugih z zdravilom povezanih povišanj incidenc tumorjev katerega koli organa ni bilo.
They could be signs of peripheral neuropathy, due to side effects of Yargesa or they could be due to existing conditions. 
To so morda znaki periferne nevropatije, ki nastanejo zaradi neželenih učinkov zdravilaYargesa, morda pa so vzrok zanje druge obstoječe bolezni.
Most serious side effects 
Najresnejši neželeni učinki
There is a close relationship between renal function and clearance of miglustat, and exposure to miglustat is markedly increased in patients with severe renal impairment (see section 5.2). 
Delovanje ledvic močno vpliva na očistek miglustata, izpostavljenost miglustatu je opazno višja pri bolnikih s hudo okvarjenim delovanjem ledvic (glejte poglavje 5.2).
Small mean reductions in haemoglobin [-0.95 g/dL (95% CI: -1.38, -0.53)] and platelet count [-44.1 × 109/L (95% CI: -57.6, -30.7)] were observed between baseline and end of study. 
Med izhodiščem in koncem študije so opazili majhno povprečno zmanjšanje hemoglobina [-0,95 g/dl (95-odstotni IZ: -1,38, -0,53)] in število trombocitov [-44,1 × 109/l (95-odstotni IZ: -57,6, -30,7)].
EU/1/17/1176/001 
ŠTEVILKA(E) DOVOLJENJA(DOVOLJENJ) ZA PROMET EU/1/17/1176/001
Contraceptive measures should be used by women of childbearing potential. 
Ženske v rodni dobi morajo uporabljati učinkovito kontracepcijo.
Very common effects - may affect more than 1 in 10 people The most common side effects are diarrhoea, flatulence (wind), abdominal (stomach) pain, weight loss and decreased appetite. 
Zelo pogosti neželeni učinki - pojavijo se lahko pri več kot 1 od 10 bolnikov Najbolj pogosti neželeni učinki so driska, flatulenca (vetrovi), bolečine v trebuhu, izguba telesne mase in zmanjšanje teka.
A mean increase in haemoglobin concentration of 0.26 g/dl and a mean platelet count increase of 8.29 × 109/l were observed. 
Opažali so povprečno povišanje koncentracije hemoglobina za 0,26 g/dl ter povprečno povečanje koncentracije trombocitov za 8,29 × 109/l.
Take the next capsule at the usual time. 
Če ste pozabili vzeti zdravilo Yargesa Kapsulo vzemite ob običajnem času.
Miglustat has been studied in indications where certain events reported as adverse reactions, such as neurological and neuropsychological symptoms/signs, cognitive dysfunction and thrombocytopenia could also be due to the underlying conditions. 
Miglustat so proučevali v zvezi z indikacijami, pri katerih bi bili lahko nekateri neželeni učinki, kot so nevrološki in nevropsihološki simptomi/znaki, kognitivna disfunkcija in trombocitopenija, tudi posledica bolezni, zaradi katere se bolnik zdravi.
This leaflet was last revised in 
Navodilo je bilo nazadnje revidirano dne <{MM/LLLL}> <{mesec LLLL}>.
Male patients should maintain reliable contraceptive methods while taking Yargesa. 
Bolniki moškega spola naj v času jemanja zdravila Yargesa uporabljajo zanesljive kontracepcijske metode.
Changes in lactation were observed in female rats in a 1-year study. 
V enoletni študiji so opazili spremembe pri dojenju pri podganjih samicah.
Yargesa contains the active substance miglustat which belongs to a group of medicines that affect metabolism. 
Zdravilo Yargesa vsebuje učinkovino miglustat, ki spada v skupino zdravil, ki vplivajo na presnovo.
Do not give this medicine to children and adolescents (below 18 years old) with type 1 Gaucher disease because it is not known if it works in this disease. 
Tega zdravila ne dajajte otrokom in mladostnikom (mlajšim od 18 let) z Gaucherjevo boleznijo tipa 1,
The benefit of treatment with Yargesa for neurological manifestations in patients with Niemann-Pick type C disease should be evaluated on a regular basis, e.g. every 6 months; continuation of therapy should be reappraised after at least 1 year of treatment with Yargesa. 
Koristi zdravljenja z zdravilom Yargesa pri nevroloških manifestacijah pri bolnikih z NiemannPickovo boleznijo tipa C je treba redno preverjati, npr. vsakih 6 mesecev; za nadaljevanje terapije se je treba ponovno odločiti po vsaj 1-letnem zdravljenju z zdravilom Yargesa.
Miglustat is an inhibitor of glucosylceramide synthase, the enzyme responsible for the first step in the synthesis of most glycolipids. 
Miglustat je zaviralec glukozilceramid-sintaze, ki je odgovoren za prvi korak v sintezi večine glikolipidov.
Studies in the rat have shown that miglustat adversely affects spermatogenesis and sperm parameters, and reduces fertility (see sections 4.6 and 5.3). 
Študije na podganah so pokazale, da miglustat neželeno vpliva na spermatogenezo in parametre spermijev ter zmanjšuje plodnost (glejte poglavji 4.6 in 5.3).
In patients with type 1 Gaucher disease, monitoring of platelet counts is recommended. 
Pri bolnikih z Gaucherjevo boleznijo tipa 1 se priporoča nadziranje števila trombocitov.
NAME OF THE MARKETING AUTHORISATION HOLDER Piramal Critical Care B.V. 
IME IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM Piramal Critical Care B.V.
Your doctor will perform some tests before and during treatment with Yargesa to assess this (see section 2). 
Zdravnik bo to ocenil z nekaj preskusi pred zdravljenjem z zdravilom Yargesa in med zdravljenjem (glejte poglavje 2).
Your doctor may reduce your dose, e.g., to one capsule (100 mg) once or twice a day, if you suffer from diarrhoea when taking Yargesa (see section 4). 
Vaš zdravnik lahko zmanjša odmerek, npr. na eno kapsulo (100 mg) enkrat ali dvakrat dnevno, če imate med jemanjem zdravila
Yargesa works by inhibiting the enzyme called ‘glucosylceramide synthase' which is responsible for the first step in the synthesis of most glycosphingolipids. 
Zdravilo Yargesa deluje tako, da zavira delovanje encima, ki se imenuje 'glukozilceramid sintaza', ki je odgovoren za prvi korak sinteze večine glikosfingolipidov.
Regular monitoring of vitamin B12 level is recommended because of the high prevalence of vitamin B12 deficiency in patients with type 1 Gaucher disease. 
Zaradi visoke prevalence pomanjkanja vitamin B12 pri bolnikih z Gaucherjevo boleznijo tipa 1 se priporoča redno spremljanje ravni vitamina B12.
Depression, insomnia, libido decreased Nervous system disorders Very common 
Pogosto depresija, insomnia, zmanjšan libido
Sometimes your doctor will need to reduce the dose or stop Yargesa treatment to stop the tremor. 
Lahko se zgodi, da bo moral zdravnik, da bi odpravil tremor, znižati vaš odmerek zdravila Yargesa ali prekiniti zdravljenje z njim.
All patients should undergo baseline and repeat neurological evaluation. 
Vse bolnike je treba ob izhodišču in kasneje ponovno nevrološko oceniti.
Gastrointestinal events, mainly diarrhoea, have been observed in more than 80% of patients, either at the outset of treatment or intermittently during treatment (see section 4.8). 
Pri več kot 80 % bolnikov so na začetku zdravljenja ali občasno med zdravljenjem opažali neželene učinke na prebavila, zlasti drisko (glejte poglavje 4.8).
In patients with an adjusted creatinine clearance of 50-70 ml/min/1.73 m2, administration should commence at a dose of 100 mg twice daily in patients with type 1 Gaucher disease and at a dose of 200 mg twice daily (adjusted for body surface area in patients below the age of 12) in patients with Niemann-Pick type C disease. 
Pri bolnikih s prilagojenim očistkom kreatinina 50-70 ml/min/1,73 m2 uporabo začnemo z odmerkom 100 mg dvakrat dnevno pri bolnikih z Gaucherjevo boleznijo tipa 1 in z odmerkom 200 mg dvakrat dnevno (prilagojeno na površino telesa pri bolnikih, starih manj kot 12 let) pri bolnikih z Niemann-Pickovo boleznijo tipa C.
Studies in animals have shown reproductive toxicity, including dystocia (see section 5.3). 
Študije na živalih so pokazale vpliv na sposobnost razmnoževanja, vključno z distocijo (glejte poglavje 5.3).
Until further information is available, it is advised that before seeking to conceive, male patients should cease Yargesa and maintain reliable contraceptive methods for 3 months thereafter. 
Dokler ne bo na voljo več informacij, je treba moškim svetovati, da pred zaploditvijo prenehajo uporabljati zdravilo Yargesa in še tri mesece potem uporabljajo zanesljivo metodo kontracepcije.
A total daily dose of 300 mg miglustat administered in three divided doses was used in the above two studies. 
V dveh zgoraj omenjenih študijah so jemali skupni dnevni odmerek 300 mg miglustata, razdeljen na tri ločene odmerke.
The benefit of treatment with Yargesa for neurological manifestations in patients with Niemann-Pick type C disease should be evaluated on a regular basis, e.g. every 6 months; continuation of therapy should be reappraised after at least 1 year of treatment with Yargesa, (see section 4.4). 
Koristi zdravljenja z zdravilom Yargesa pri nevroloških manifestacijah pri bolnikih z NiemannPickovo boleznijo tipa C je treba redno preverjati, npr. vsakih 6 mesecev; za nadaljevanje terapije se je treba ponovno odločiti po vsaj 1-letnem zdravljenju z zdravilom Yargesa (glejte poglavje 4.4).
Studies in the rat have shown that miglustat adversely affects sperm parameters (motility and morphology) thereby reducing fertility (see sections 4.4 and 5.3). 
Študije pri podganah so pokazale, da miglustat negativno vpliva na parametre sperme (gibljivost in obliko), s čimer zmanjša plodnost (glejte poglavji 4.4 in 5.3).
If you get a slight tremor, usually trembling hands, seek medical advice from your doctor as soon as possible. 
Če med zdravljenjem z zdravilom Yargesa izkusite blag tremor, običajno tresenje rok, to čim prej sporočite svojemu zdravniku.
The inhibitory action on glucosylceramide synthase forms the rationale for substrate reduction therapy in Gaucher disease. 
Zaviralno delovanje na glukozilceramid-sintazo je podlaga za zdravljenje z zmanjšanjem substrata pri
What Yargesa contains 
Kaj vsebuje zdravilo Yargesa
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. 
Preobčutljivost za učinkovino ali katero koli pomožno snov, navedeno v poglavju 6.1. 4.4 Posebna opozorila in previdnostni ukrepi
Pack size of 84 capsules. 
Velikost pakiranja: 84 kapsul.
Each hard capsule contains 100 mg miglustat. 
Ena trda kapsula vsebuje 100 mg miglustata.
A second open, controlled study of miglustat randomised 36 patients who had received a minimum of 2 years of treatment with ERT, into three treatment groups: continuation with imiglucerase, imiglucerase in combination with miglustat, or switch to miglustat. 
36 bolnikov, ki so se že vsaj dve leti zdravili z ERT: nadaljevanje zdravljenja z imiglucerazo, kombinacija imigluceraze in miglustata ali prehod na miglustat.
• Yargesa is used to treat mild to moderate type 1 Gaucher disease in adults. 
• Zdravilo Yargesa se uporablja za zdravljenje blage do zmerne Gaucherjeve bolezni tipa 1 pri odraslih.
• measurement of vitamin B12 levels 
- pregled živcev v vaših rokah in nogah - meritev ravni vitamina B12
Ask your pharmacist how to throw away medicines you no longer take. 
O načinu odstranjevanja zdravila, ki ga ne potrebujete več, se posvetujte s farmacevtom.
The recommended dose for the treatment of adolescent patients (12 years of age and above) with NiemannPick type C disease is 200 mg three times a day. 
Pediatrična populacija Priporočeni odmerek za zdravljenje mladostnikov (starih 12 let in več) z Niemann-Pickovo boleznijo tipa C je 200 mg trikrat dnevno.
Miglustat has not been evaluated in patients with a history of significant gastrointestinal disease, including inflammatory bowel disease. 
Miglustata pri bolnikih z anamnezo pomembnega obolenja prebavil, vključno z vnetno črevesno boleznijo, niso vrednotili.
4.4 Special warnings and precautions for use 
Opozorila in previdnostni ukrepi
There was no drug-related increase in tumour incidence in male or female rats in any other organ. 
Drugih z zdravilom povezanih povišanj incidenc tumorjev kateregakoli drugega organa pri samcih ali samicah podgan ni bilo.
Male patients should maintain reliable contraceptive methods while taking Yargesa (see sections 4.4 and 5.3). 
Moški morajo ves čas uporabe zdravila Yargesa uporabljati zanesljiv način kontracepcije (glejte poglavji 4.4 in 5.3).
Elderly There is no experience with the use of Yargesa in patients over the age of 70. 
Ni izkušenj z zdravljenjem bolnikov, starih več kot 70 let, z zdravilom Yargesa.
There was a mean increase of 22.2 × 109/l in platelet count, and a mean increase of 0.95 g/dl in haemoglobin concentration. 
Povprečno povečanje koncentracije trombocitov je bilo 22,2 × 109/l, povprečno povišanje koncentracije hemoglobina pa 0,95 g/dl.
Marketing Authorisation Holder and Manufacturer Piramal Critical Care B.V. 
Imetnik dovoljenja za promet z zdravilom in izdelovalec: Piramal Critical Care B.V.
• monitoring growth if you are a child or adolescent with Niemann-Pick type C disease 
- nadziranje rasti, če ste otrok ali mladostnik z Niemann-Pickovo boleznijo tipa C - nadziranje števila trombocitov v krvi.
Adverse events observed included granulocytopenia, dizziness and paraesthesia. 
Opaženi neželeni učinki so bili granulocitopenija, omotičnost in parestezija.
The pharmacokinetics of miglustat is similar in adult type 1 Gaucher disease patients and Niemann-Pick type C disease patients when compared to healthy subjects. 
Farmakokinetika miglustata je podobna pri odraslnih bolnikih z Gaucherjevo boleznijo tipa 1 in bolenikih z Niemann-Pickovo boleznijo tipa C, primerjano pri odraslih osebah.
Carcinomas in the large intestine occurred occasionally at all doses with a statistically significant increase in the high dose group. 
Karcinomi debelega črevesa so se pojavili občasno pri vseh odmerkih, s statistično pomembnim povečanjem pri največjem odmerku.Pomembnost teh ugotovitev za človeka ni mogoče izključiti.
Other medicines and Yargesa Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines. 
Obvestite zdravnika, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katero koli drugo zdravilo.
Dosage in Niemann-Pick type C disease 
Odmerjanje pri Niemann-Pickovi bolezni tipa C
Psychiatric disorders Common 
Psihiatrične motnje